Enveric Biosciences Inc Quick Ratio (ENVB) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
ENVB's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth
In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 9.63 above Enveric Biosciences Inc average.
Within Major Pharmaceutical Preparations industry 111 other companies have achieved higher Quick Ratio than Enveric Biosciences Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 326 to 415.
Cambridge, Mass. - Enveric Biosciences Patents Pathways to Mental Health Innovation In the dynamic intersection of biotechnology and psychiatry, Enveric Biosciences (NASDAQ: ENVB) stands as a forward-thinking entity, pioneering within the realm of neuroplastogenic therapeutics. Recently, the company celebrated a noteworthy stride in its strategic mission with the issuance of its 23rd patent by the United States Patent and Trademark Office (USPTO). This pivotal patent fortifies Enveric s intellectual property estate, serving as a cornerstone in the development of innovative small-molecule therapeutics targeting psychiatric and neurological disorders.The reinforcement of Enveric s patent portfolio signals a pivotal advancement, encapsulating the essence of neuroplasticity with novel compounds geared towards transformative mental health treatments. As the global scientific community intensifies its focus on neurotherapeutic initiatives, Enveric s expanding arsenal of intellectual property assets marks a significant contribution, underscoring the company s commitment to ameliorating mental health challenges through innovative science.
Enveric Biosciences Inc. (NASDAQ: ENVB), a biotechnology firm concentrating on pioneering neuroplastogenic small molecule therapeutics targeting psychiatric and neurological conditions, has recently made significant progress in the realm of neurodegenerative disease treatment. This article seeks to provide an view of Enveric’s latest scientific advancements and the accompanying financial landscape. Scientific Advancements On an optimistic note, Enveric Biosciences has announced the filing of a new provisional patent application related to their ongoing research on neuroplastogens. The application includes claims to innovative methods and pharmaceutical formulations pertaining to a novel family of molecules. These molecules exhibit potential benefits in addressing neurodegenerative diseases, a progressive and challenging area within neuroscience.
In a significant step towards revolutionizing the treatment landscape for mental health disorders, Enveric Biosciences (NASDAQ: ENVB) has received a U.S. patent for its EVM401 series of compounds. This development signals a promising advancement in the realm of biopharmaceuticals aimed at combating depression, anxiety, and addiction-related conditions. The issuance of U.S. Patent No. 12,195,439 on January 14, 2025, marks a pivotal moment for Enveric as it consolidates its position in an increasingly competitive market. Innovative Compounds Overview The patented compounds, classified as Cl-Substituted Isopropylamine Fused Heterocyclic Mescaline Derivatives, leverage the psychopharmacological properties of mescaline while enhancing their therapeutic potential through molecular modifications. These new derivatives are designed to act as neuroplastogenic agents, promoting neuroplasticity the brain s ability to reorganize itself by forming new neural connections. This property is particularly crucial for addressing treatment-resistant cases of mental health disorders, where conventional therapies often fall short.
On the trailing twelve months basis ENVB Cash & cash equivalent more than doubled by 191.12 % in Q2 2026 year on year, while Current Liabilities soared to $1 millions, this led to increase in in Enveric Biosciences Inc 's Quick Ratio to 6.88, above ENVB average Quick Ratio. Quick Ratio is the average cumulative value over the last four quarters.
Among companies operating within Major Pharmaceutical Preparations industry 420 other companies have achieved higher Quick Ratio than Enveric Biosciences Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 2946 to 3547.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
